The Effect of Fiasp (Fast-acting Insulin Aspart) in Type 1 Diabetes Patients Using Continuous Glucose Monitoring / Flash Glucose Monitoring in Real-world Clinical Practice in Sweden. A Non-interventional, Retrospective Chart and Database Review Study
Latest Information Update: 12 Apr 2022
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
Most Recent Events
- 19 Feb 2021 Status changed from recruiting to completed.
- 18 Dec 2020 Planned End Date changed from 30 Oct 2020 to 21 Dec 2020.
- 18 Dec 2020 Planned primary completion date changed from 30 Oct 2020 to 21 Dec 2020.